DC4U’s GlycoDCTM targeting technology can be applied to achieve suppression of autoimmune responses. This can be achieved via induction of regulatory T-cells by glycan-modification of disease specific self-antigens or peptides derived from these antigens.
We recently obtained strong evidence that certain glycans are involved in tolerance induction. Conjugation of these inhibitory glycans to self-antigen-peptides endows dendritic cells with tolerogenic properties, as shown by regulatory T-cell (Treg) induction and inhibition of effector T cell generation. This tolerogenic feature of the DCs is even maintained under inflammatory conditions. Importantly, suppression via glycan-antigen targeted DCs occurs in an antigen-specific fashion.
We foresee the potential application of this technology in development of agents for the treatment of autoimmune diseases. Glycan conjugated disease specific antigens may effectively be used for the treatment of autoimmune diseases such as Multiple Sclerosis, Rheumatoid Arthritis, Diabetes type 1, gastritis and Inflammatory Bowel Disease. This will enable a whole new area of treatment for autoimmune diseases. We currently run a Multiple Sclerosis immunotherapy development program.
To exploit the potential for DC4U’s GlycoDCTM targeting technology in the treatment of auto-immune diseases, we offer business and partnering options to life science companies actively involved in research and development in this area.